ProKidney (NASDAQ:PROK - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03), Zacks reports. The company had revenue of $0.08 million for the quarter.
ProKidney Trading Up 1.9 %
NASDAQ:PROK traded up $0.02 on Friday, reaching $0.96. The stock had a trading volume of 824,560 shares, compared to its average volume of 656,479. The company has a 50-day moving average of $1.41 and a 200 day moving average of $1.72. The stock has a market cap of $280.05 million, a P/E ratio of -1.75 and a beta of 1.38. ProKidney has a 12-month low of $0.87 and a 12-month high of $4.44.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Read More
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
